Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have been given an average rating of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $12.60.

Several research analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Immuneering in a research report on Wednesday, August 7th. Chardan Capital lowered their target price on Immuneering from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th.

Institutional Trading of Immuneering

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new position in shares of Immuneering during the 2nd quarter worth about $492,000. Renaissance Technologies LLC acquired a new position in shares of Immuneering during the second quarter worth approximately $447,000. Vanguard Group Inc. lifted its holdings in shares of Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after buying an additional 129,851 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Immuneering during the second quarter worth approximately $67,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Immuneering during the second quarter worth approximately $44,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Price Performance

IMRX stock opened at $1.03 on Monday. The firm has a market capitalization of $30.54 million, a P/E ratio of -0.55 and a beta of -0.61. Immuneering has a 52-week low of $1.00 and a 52-week high of $10.25. The company’s 50 day simple moving average is $1.27 and its 200-day simple moving average is $2.58.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05. Sell-side analysts predict that Immuneering will post -1.93 EPS for the current fiscal year.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.